ChanTest Corporation (Cleveland, OH USA) has launched a new in vitro cardiac safety assessment tool, based on the combined technologies of microelectrode array (MEA) and human induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The assay is available with Axiogenesis Cor.4U human iPSC cardiomyocytes, following a thorough validation.

For the complete release, click here.

To learn more about the application of stem cell-derived cardiomyocytes and MEA in drug discovery and development, click here.

iPS Academia Japan, Inc and Axiogenesis have announced an expansion of their existing partnership.  Under the expanded relationship, iPS Academia has rights to sub-license certain patents within the Axiogenesis IP portfolio related to drug development, tissue models and disease models.  For the complete news release, click here.

The USPTO approved a patent for Axiogenesis AG for the invention of its in vitro assay to screen pharmaceutical drug candidates for effectiveness and safety in treating Hypertrophic Cardiomyopathy (HCM).

The assay, which has previously received patents in Europe and Japan, is based on induced pluripotent stem (iPS) cell technology. Axiogenesis has developed the ability to induce HCM in iPS cell-derived cardiomyocytes, creating an in vitro model of the disease that can be used to evaluate drug candidates and molecular targets.

Hypertrophic Cardiomyopathy, also known as cardiac hypertrophy, is a potentially fatal disease that can develop in as many as 5 in 1,000 people worldwide.

The patent is far-reaching and broadly covers mechanisms for inducing cardiac hypertrophy in any stem cell-derived cardiomyocytes, including Axiogenesis’ Cor.4U® human iPS cell-derived cardiomyocytes and Cor.At® murine stem cell-derived cardiomyocytes.

Read the complete news release.

  • 1
  • 2


Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)




Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter


Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10